Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-11 22:30 • The Motley Fool Positive Axe Cap view: Selective

Micron's stock has declined 18% from its June 2026 high of $1,255 to $1,030. While the company has historically experienced steep drawdowns during memory market cycles, the article argues that AI-driven demand for high-bandwidth memory (HBM) chips and enterprise SSDs could fundamentally extend this growth cycle differently than past cycles. Analysts project 55% revenue and 67% EPS growth through fiscal 2028, with the stock trading at a relatively cheap valuation of 6x earnings.

Axe note: Micron’s 18% pullback might be a pause before further gains driven by AI demand for memory.

2026-10-11 22:18 • The Motley Fool Positive Axe Cap view: Selective

The article highlights three monthly dividend-paying investments yielding over 5% for income-seeking investors: Realty Income (O), a retail REIT with 31 consecutive years of dividend increases; UDR, an apartment complex owner that recently switched to monthly payouts with a 5.2% yield; and the iShares Preferred and Income Securities ETF (PFF), offering diversified exposure to preferred stocks with a 5.4% yield.

Axe note: Exploring three monthly dividend payers with yields above 5%, and their relevance to rand-based income seekers.

2026-10-11 22:17 • The Motley Fool Positive Axe Cap view: Selective

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio), higher dividends (1.9% yield), and a concentrated portfolio of 26 pharmaceutical companies with an established 15-year track record. Simplify Health Care ETF (PINK) provides broader healthcare exposure through active management of 58 positions with a unique charitable structure donating profits to cancer research, though it carries higher fees (0.51%) and lower yields (0.8%). For most long-term investors, PPH is recommended for its fundamentals, while PINK appeals to those seeking active management and charitable impact.

Axe note: PPH’s low costs and strong pharma focus make it a better long-term pick than PINK for most investors.